Filter by audience:
Oral sessions summaries
DFN-15 (Celecoxib Oral Solution, 25 Mg/ml) in the Acute Treatment of Episodic Migraine: Efficacy Results from Two Phase III Randomized, Double-blind, Placebo-controlled Studies
Expert commentary by by A. Laine Green, MSc, MD, FRCPC, FAHS
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-drug Interaction Study with Lasmiditan
Expert commentary by by A. Laine Green, MSc, MD, FRCPC, FAHS
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Rimegepant 75 mg Provides Early and Sustained Relief of Migraine with a Single Oral Dose: Results from 3 Phase 3 Clinical Trials
Expert commentary by Stephanie J. Nahas, MD, MSEd, FAHS, FAAN
AHSAM 2020 - Oral session
Published on September 11, 2020
Identify Biomarkers in Migraine and Cluster Headache by Improving Experimental Design
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Wolff Award: Cognitive Networks Disarrangement in Patients with Migraine Predicts Cutaneous Allodynia
AHSAM 2020 - Oral session
Published on July 17, 2020
Early Career Award: Alterations in Functional Connectivity during Different Phases of the Triggered Migraine Attack
AHSAM 2020 - Oral session
Published on July 17, 2020
Solomon Award Lecture: Observations 2020 - 'Teaching Headache'
AHSAM 2020 - Oral session
Published on July 17, 2020
Graham Award: Practical Approach to Eye Pain and Photophobia
AHSAM 2020 - Oral session
Published on July 17, 2020
Headache & COVID-19: A Short-term Challenge with Long-term Insights
AHSAM 2020 - Oral session
Published on July 17, 2020
COVID-19 and Headache: The New York Experience
AHSAM 2020 - Oral session
Published on July 17, 2020
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers
AHSAM 2020 - Oral session
Published on July 17, 2020
A Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Expert commentary by Carrie Dougherty, MD, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
Endogenous Analgesia in Patients with Chronic Migraine: A Study of Conditioned Pain Modulation
Expert commentary byThomas N. Ward, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Exploring the Boundaries Between Episodic and Chronic Migraine: Results from the CaMEO Study
Expert commentary byThomas N. Ward, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Inter and Intra-individual Differences in the Association Between Menstruation and Migraine
Expert commentary by Huma U. Sheikh, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Role of PAR-2 Receptors in Migraine Using a Novel, Translatable Injury-Free Preclinical Model
Expert commentary by Andrew Russo, PhD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Sustained Efficacy and Safety of Erenumab in Patients with Episodic Migraine who Failed 2–4 Prior Preventive Treatments: 2-year Interim Results of the LIBERTY Open-label Extension Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Real World Efficacy, Tolerability and Safety Study of Ubrogepant, Rimegepant, and Lasmiditan
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Correlation of Pediatric Headache-related Functional Disability Inventory (FDI) and Prolonged School Absence
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Retrospective Review of the Use of Anti-CGRP Monoclonal Antibodies to Treat Headaches in Patients with Idiopathic Intracranial Hypertension
Expert commentary by Deborah I. Friedman, MD, MPH, FAAN, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
The Role of Cerebellar CGRP in Migraine-like Behavior
Expert commentary by Amynah Pradhan, PhD
AHSAM 2020 - Oral session
Published on July 23, 2020
Characteristics of Individuals with Migraine Who Are Eligible for Novel CGRP Monoclonal Antibodies: Results of the OVERCOME Study
Expert commentary by Carrie Dougherty, MD, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
Multiple, Once-daily, Oral Doses of 170 Mg Atogepant for 28 Days Are Safe and Well Tolerated with No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults
Expert commentary by Jessica Ailani, MD
AHSAM 2020 - Oral session
Published on September 3, 2020
Eptinezumab Demonstrated Migraine Preventive Efficacy on Day 1 After Dosing: Closed Testing Analysis from PROMISE-1 and PROMISE-2
Expert commentary by Jessica Ailani, MD
AHSAM 2020 - Oral session
Published on September 3, 2020
Survivors of Military Sexual Trauma Face Increased risk of Migraine Headaches and Worse Headache Care
Expert commentary by Gretchen E. Tietjen, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Improved Functionality, Satisfaction, and Global Impression of Change with Ubrogepant for the Acute Treatment of Migraine in Triptan Insufficient Responders
Expert commentary by Randolph W. Evans, MD
AHSAM 2020 - Oral session
Published on September 11, 2020
Efficacy and Safety of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) in the Acute Treatment of Migraine: Results from the MOMENTUM Phase 3 Trial
Expert commentary by Randolph W. Evans, MD
AHSAM 2020 - Oral session
Published on September 11, 2020
Identifying Barriers to Care-seeking, Diagnosis, and Preventive Medication Among Those with Migraine: Results of the OVERCOME Study
Expert commentary by Thomas N. Ward, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Real-World Experience with Calcitonin Gene-related Peptide (CGRP) Antagonists in the Treatment of Migraine
Expert commentary by Morris Levin, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Consistency of the Efficacy of Single Use and Repeated Use of M207 (Intracutaneous Microneedle Zolmitriptan) for the Acute Treatment of Migraine; Results for Pain Freedom, Pain Relief, and Sustained Pain Freedom and Pain Relief
Expert commentary by Morris Levin, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Pooled Analysis of Cardiovascular Safety with Fremanezumab Treatment in Patients with Migraine by Number of Cardiovascular or Cerebrovascular Risk Factors
Expert commentary by Morris Levin, MD
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
A Real-World Comparison of Erenumab and Galcanezumab in a Tertiary Headache Center
Expert commentary by Jessica Ailani, MD
AHSAM 2020 - Oral session
Published on September 17, 2020
The Impact of Migraine on Pregnancy Plan: Insights from the American Registry for Migraine Research (ARMR)
Expert commentary by Rebecca Burch, MD, FAHS
AHSAM 2020 - Oral session
Published on September 24, 2020 | NEW
Migraine as a Risk Factor for Dementia: A National Register-based Follow-up Study
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Development of a Visualization Tool for Tracking Modifiable Risk Factors for Progression from Episodic to Chronic Migraine
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Improving Headache Management in the Pediatric Emergency Department
AHSAM 2020 - Oral session
Published on July 30, 2020
Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-year Follow-up Survey Results
Expert commentary by Marcy Yonker, MD, FAHS
AHSAM 2020 - Oral session
Published on July 30, 2020
Improving Headache Management in the Pediatric Emergency Department
Expert commentary by Amy A. Gelfand, MD, MAS, FAHS
AHSAM 2020 - Oral session
Published on October 2, 2020 | NEW
Exploring Naturally Occurring Clinical Subgroups of Post-traumatic Headache
Expert commentary by Nada Hindiyeh, MD
AHSAM 2020 - Oral session
Published on July 23, 2020
Effects of Pre-injury Migraine Frequency on Post-traumatic Headache Recovery in the General Adult Population: The Toronto Concussion Study
Expert commentary by Nada Hindiyeh, MD
AHSAM 2020 - Oral session
Published on July 23, 2020
Mild TBI induces long-lasting sensitization to pain in mice
Expert commentary by Andrew Russo, PhD
AHSAM 2020 - Oral session
Published on August 27, 2020
